We characterize sgCas9‐AdV/Gel in terms of AdV release, transduction, and PD‐L1 gene editing efficiency, and further use this system to assess the therapeutic effect across multiple tumor models, which is demonstrated to be associated with the increased antitumor immune response but reduced antiviral immunity. This evidence concerns the gene CD274 and neoplasm.